bavituximab

Home
Ligands
bavituximab

GtoPdb Ligand ID: 8002

Synonyms: Tarvacin ch3G4

Comment: Bavituximab is the first monoclonal antibody directed against phosphatidylserine, and is being investigated as a antineoplastic agent. Bavituximab belongs to an emerging class of antibodies known as vascular targeting agents (VTAs) which bind selectively to antigens present on tumour vascular cells. Typical VTAs either recruit host effector cells to destroy the tumour or are coupled to agents such as toxins, anticoagulants or pro-apoptotic drugs that occlude or destroy tumour blood vessels [3].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

No information available.

No information available.

Summary of Clinical Use
Phase 2I clinical trial NCT01999673 is assessing bavituximab+docetaxel vs. docetaxel as a treatment for late-stage non-squamous non-small-cell lung cancer. Phase 2 trials for breast cancer, metastatic pancreatic cancer, liver cancer and hepatitis C infection have all been completed.

Summary of Clinical Use

Phase 2I clinical trial NCT01999673 is assessing bavituximab+docetaxel vs. docetaxel as a treatment for late-stage non-squamous non-small-cell lung cancer. Phase 2 trials for breast cancer, metastatic pancreatic cancer, liver cancer and hepatitis C infection have all been completed.

Mechanism Of Action and Pharmacodynamic Effects
Bavituximab binds to phosphatidylserine (PS, in complexes also containing the PS-binding plasma protein βglycoprotein 1 (β2GP1) [4]) which is exposed on the surface of tumour endothelial vascular cells [2] and some virally infected cells. Bavituximab binding leads to disruption of tumour vasculature which causes tumour cell death [1,4-5] and induces pro-inflammatory responses by neutralising PS's anti-inflammatory signalling action via monocytes and macrophages [4]. Bavituximab's mechanism of action is designed to restrict damage to virally-infected or malignant cells, sparing normal cells and tissues [1].

Mechanism Of Action and Pharmacodynamic Effects

Bavituximab binds to phosphatidylserine (PS, in complexes also containing the PS-binding plasma protein βglycoprotein 1 (β2GP1) [4]) which is exposed on the surface of tumour endothelial vascular cells [2] and some virally infected cells. Bavituximab binding leads to disruption of tumour vasculature which causes tumour cell death [1,4-5] and induces pro-inflammatory responses by neutralising PS's anti-inflammatory signalling action via monocytes and macrophages [4]. Bavituximab's mechanism of action is designed to restrict damage to virally-infected or malignant cells, sparing normal cells and tissues [1].